Navigation Links
FDA Approves KAPIDEX(TM) (Dexlansoprazole) delayed release capsules for the Treatment of GERD
Date:1/30/2009

First proton pump inhibitor (PPI) with a Dual Delayed Release(TM) (DDR) formulation

DEERFIELD, Ill., and OSAKA, Japan, Jan. 30 /PRNewswire/ -- Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration (FDA) approved KAPIDEX(TM) (dexlansoprazole) delayed release capsules for the once-daily, oral treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE. KAPIDEX (30 mg and 60 mg) is the first proton pump inhibitor (PPI) with a Dual Delayed Release(TM) (DDR) formulation designed to provide two separate releases of medication.

"Through the discovery, development and commercialization of new medicines, Takeda has been a leader in acid-related therapy for more than 15 years and is committed to bringing new therapies to market," said Alan MacKenzie, president and CEO, Takeda Pharmaceuticals North America. "KAPIDEX is a new, innovative treatment option in the well-established PPI market."

PPIs work by reducing acid production by turning off many of the acid pumps in the stomach. KAPIDEX contains two types of enteric-coated granules resulting in a concentration-time profile with two distinct peaks: the first peak occurs one to two hours after administration, followed by a second peak within four to five hours. In addition, KAPIDEX can be taken regardless of when food is consumed.

"People with GERD often suffer with heartburn symptoms during the day and night," said David Peura, MD, professor of medicine, University of Virginia Health System. "In the pivotal Phase 3 clinical studies, KAPIDEX demonstrated the ability to provide up to 24-hour heartburn relief with a side effect profile similar to lansoprazole. KAPIDEX, with its DDR formulation, is a new and exciti
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
3. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
4. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
7. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
11. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... August 27, 2014 Riviera Beach, ... announcing the creation of the Sancilio Scientific Advisory ... the SCI’s philosophy of looking to nature for ... development actions are based on sound scientific data, ... Advisory Board provides a vehicle for SCI to ...
(Date:8/27/2014)... NJ (PRWEB) August 27, 2014 WriteResult, ... services – has once again shown superiority when it ... sponsor by completing the ePRO portion of their most ... The Japan-based pharma chose WriteResult’s digital writing platform ... trials – the first to complete drew data from ...
(Date:8/26/2014)... , Aug. 26, 2014 An analysis ... structures of all Mers CoV virus strains ... structures back to 2012.  This conservation and sharing of ... a Synthetic Mers CoV Blocker-Vaccine™ candidate, as it did for ... vaccine, both of which have been found to be ...
(Date:8/26/2014)... LONDON , Aug. 26, 2014 An ... gene structures of all Dengue virus strains in Pubmed, ... structures back to 1944. This conservation and sharing of ... a Synthetic Dengue Blocker-Vaccine™ candidate, as it did for ... vaccine, both of which have been found to be ...
Breaking Biology Technology:New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2
... Corporation (NASDAQ: LIFE ) today announced it ... Conference on Tuesday, September 20 at 8:00am ET.  Greg ... present on behalf of the company. The company will ... weeks following the conference on the Life Technologies, investor ...
... Aug. 29, 2011 Chemical Abstracts Service ( CAS ... that Syngene International , an internationally reputed contract ... biotechnology company, has signed a three-year contract to provide ... award-winning chemistry research tool. SciFinder offers ...
... 26, 2011 Quantum Learning, Inc. (QLI), ... programs, and Jay Elliot, author of the book " ... announced today a licensing agreement.  Under the terms of ... training program called "Market-Leading Innovation™ (The path to Innovation ...
Cached Biology Technology:Life Technologies to Present at the UBS 2011 Global Life Sciences Conference 2Syngene Expands Ongoing Relationship with CAS to Provide SciFinder® to All Its Scientists 2Syngene Expands Ongoing Relationship with CAS to Provide SciFinder® to All Its Scientists 3Quantum Learning Signs Licensing Agreement with Jay Elliot, Author of "The Steve Jobs Way" 2Quantum Learning Signs Licensing Agreement with Jay Elliot, Author of "The Steve Jobs Way" 3
(Date:8/26/2014)... has recommended investing in dog owner education and facilities as ... obesity in both people and their pets. , In a ... that access to dog-friendly walking environments and better education about ... and take more exercise with their pets. , It is ... for a walk. In the UK, almost a quarter of ...
(Date:8/25/2014)... biofuels industry: "You can make anything from lignin ... pave the way to challenging that adage. The ... Laboratory (NREL) demonstrates a concept that provides opportunities ... variety of renewable fuels, chemicals, and materials for ... Through Integrated Biological Funneling and Chemical Catalysis " ...
(Date:8/25/2014)... A family of proteins that promotes virus entry ... release of HIV and other viruses, University of Missouri ... that provides new insights into our understanding of not ... other viruses," said Shan-Lu Liu, M.D., Ph.D., associate professor ... Microbiology and Immunology. , The study was recently published ...
Breaking Biology News(10 mins):Education and dog-friendly neighbourhoods could tackle obesity 2New process helps overcome obstacles to produce renewable fuels and chemicals 2MU researchers discover protein's ability to inhibit HIV release 2MU researchers discover protein's ability to inhibit HIV release 3
... and interact with human cells has been identified. This ... a recent collaborative study carried out by the University ... Finland. The findings increase our understanding of the strategies ... further facilitates the development of baculovirus for applications of ...
... of Virginia engineering professor has proposed a novel approach ... , Andres Clarens, an assistant professor of civil and ... Science, and graduate student Zhiyuan Tao have published a ... dioxide that could be stored in hydraulically fractured shale ...
... A new urine test for prostate cancer that measures ... men nationwide through the University of Michigan MLabs. The ... blood test, increases physicians, ability to pick out high-risk ... help tens of thousands of men avoid unnecessary biopsies. ...
Cached Biology News:U.Va. researcher: Methane out, carbon dioxide in? 2Prostate Cancer Foundation announces new urine test for prostate cancer available 2Prostate Cancer Foundation announces new urine test for prostate cancer available 3
... Versatile affinity matrix for the ... containing proteins or other macromolecules, Applications: ... inhibition of the interaction of pure ... protein. Removing residual SDS in 6 ...
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
Each Yeast-GFP clone represents an individual S. cerevisiae strain containing an open reading frame with a C-terminal Aequorea Victoria GFP (S65T) fusion tag....
... forces with the Mickle Laboratory Engineering Company ... This tissue sectioning system has been designed ... experiments and to be especially applicable to ... or from small organs. Its special features ...
Biology Products: